MEIP - MEI releases promising phase 1 data on zandelisib for malignancies lymphoma

MEI Pharm (MEIP) says that new data from two phase 1 trials of its phosphatidylinositol 3-kinase delta ("PI3K?") inhibitor zandelisib showed strong response rates in lymphoma and malignancies.In one of the studies, all patients with relapsed/refractory indolent B-cell malignancies and chronic lymphocytic leukemia who received zandelisib combined with BeiGene's BRUKINSA (zanubrutinib) achieved an objective response.In the other study, which tested zandelisib + rituxan, the overall response rate in patients with relapsed/refractory follicular lymphoma was 82%.MEI added that topline data from a phase 2 study is expected by the end of the year.The new data, along with a phase 3 design of a trial of zandelisib in combination with rituximab in patients with relapsed/refractory indolent non-Hodgkin's lymphoma, will be presented at next month's American Society for Clinical Oncology Annual Meeting.#ASCO21MEI shares are down 4.4% to $2.82 in morning trading.

For further details see:

MEI releases promising phase 1 data on zandelisib for malignancies, lymphoma